Please login to the form below
16
Revenue 2017Tecfidera
The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Tecfidera was produced by Biogen Idec.
EMA clears BMS’ oral multiple sclerosis drug Zeposia
There are other entrenched oral therapies to contend with, notably Biogen’s Tecfidera (dimethyl fumarate) which also has low-cost generics on the horizon that could exert downward pressure on oral
J&J aims for US approval of MS drug ponesimod
A range of blockbuster therapies are already available for MS, including Biogen’s Tecfidera (dimethyl glutamate) and new injectables like Roche’s Ocrevus (ocrelizumab). ... There is also the looming threat of generic competition to Gilenya and
Biogen triumphs over Mylan’s Tecfidera patent challenge
The challenge from Mylan focused on Biogen’s ‘514 patent on Tecfidera (dimethyl fumarate) , which is due to expire in 2028. ... Circuit to remove this patent from blocking generic competition to Tecfidera," they added.
Biogen under fire over $88,000 Vumerity annual price
Vumerity is Biogen’s answer to the patent pressures on Tecfidera, but there have been concerns that. ... patients who are stable on Tecfidera will be unwilling to to transfer to the newer drug.
Biogen’s R&D chief Ehlers heads for the exit
There are more immediate problems at Biogen however. Multiple sclerosis blockbuster Tecfidera (dimethyl glutamate) is coming under increasing competitive pressure, and analysts aren’t confident that a follow-up with an ... improved tolerability profile
Data provided by GlobalData
GlobalData is the premier source of research and consulting solutions for the pharmaceutical and medical device industries. With the combined expertise of more than 600 researchers, market analysts and consultants, we deliver high-quality, accurate and transparent industry insight that helps our clients to achieve growth and increase business value.
To find out more about how our research and consulting solutions can help you, please visit healthcare.globaldata.com
For more details on the data and methodology used to create the Top Pharma Lists, please visit PMLiVE's Top Pharma List - Methodology
COVID-19 Updates and Daily News
Featured jobs
- EMA clears BMS’ oral multiple sclerosis drug Zeposia
- Biogen delays filing of Alzheimer’s drug, which hits its share price
- EMA clears BMS’ oral multiple sclerosis drug Zeposia
- Alnylam and Vir plan gene-silencing attack on COVID-19 virus
- Merck’s Keytruda hits the mark in triple negative breast cancer
- Finalists 2020 - Communiqué Awards
- ASCO: Momentum gathers behind next wave of CAR-T therapies
- Lilly starts world first trial of an antibody drug for COVID-19
- Pfizer’s Ibrance misses the mark in early breast cancer
- Rise of the patient influencer
- Working together against COVID-19
- Vicky Bramham, Managing Director at OPEN Health PR shares tips on media relations during COVID-19
PMHub
Four Health
Beautiful things happen when you put the right ingredients together. It’s the reason that we mix behaviour change experts with...
Latest intelligence
- Working together against COVID-19
- Analysing social media conversations to see what HCPs are saying online about the global pandemic...
- Vicky Bramham, Managing Director at OPEN Health PR shares tips on media relations during COVID-19
- Vicky speaks with freelance health journalist Jacqui Thornton who gives her expert view on how best to approach media relations during this unprecedented time....
- Are biobetters a market access opportunity?
- Biobetters are biologics that have been improved compared to the marketed originator, for example in efficacy, safety, tolerability or dosing regimen....
Quick links
Infographics
